Program
apixaban
Also written as “Apixaban”, “Apixaban 5 MG” and “Apixaban 5 mg Oral Tablet”.
Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Thrombosis · Acute Coronary Syndrome · Venous Thromboembolism, led by 7 companies.
Drug pageApixaban: every studyMany companies study it; this page follows only the 37 they lead. All 179 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 260 open or running | phase 4since Jun 6, 2013 | Nov 22, 2004 | none ahead |
| Pfizer | 60 open or running | phase 4since Feb 5, 2014 | Nov 5, 2008 | none ahead |
| Artivionits history only | 10 open or running | phase 3since Oct 9, 2019 | Oct 9, 2019 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | phase 1since Feb 5, 2025 | Feb 5, 2025 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Sep 4, 2023 | Sep 4, 2023 | none ahead |
| Scotmann Pharmaceuticalsits history only | 10 open or running | phase 2since Oct 21, 2021 | Oct 21, 2021 | none ahead |
| TAHO Pharmaceuticalsits history only | 10 open or running | early phase 1since Jul 24, 2023 | Jul 24, 2023 | none ahead |
Also a collaborator on its studies: Link Medical Research AB, Parexel and PT Equilab International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 5, 2008First study: phase 2 study in Atrial FibrillationFirst studyNCT00787150 · 222 enrolled · Japan
- Feb 26, 2009Phase 2 study in Acute Coronary SyndromeNCT00852397 · 151 enrolled · Japan
- Jun 3, 2009Phase 1 study in ThrombosisNCT00914641 · 16 enrolled · United States
- Sep 20, 2011Phase 1 study in HealthyNCT01437839 · 22 enrolled · Singapore
- Jan 29, 2013Phase 3 study in Venous ThrombosisNCT01780987 · 80 enrolled · Japan
- Feb 5, 2014Phase 4 study in Atrial FibrillationNCT02100228 · 1,500 enrolled · United States, Belgium, Canada and more
TargetBeta
“Coagulation factor X inhibitor”ChEMBL 37, by rule
Other programs on F10
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rivaroxabanrule | Bayer | phase 4 | 77 |
| emicizumabrule | Hoffmann-La Roche | phase 4 | 13 |
| Factor Xrule | kedrion-s-p-a | phase 3 | 1 |
Studies
All 6 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02100228Atrial Fibrillation · United States, Belgium, Canada and more | 4 | Completed | Feb 8, 2017 | 1,500 |
| NCT01780987Venous Thrombosis · Japan | 3 | Completed | Sep 2014 | 80 |
| NCT01437839Healthy · Singapore | 1 | Completed | Oct 2011 | 22 |
| NCT00914641Thrombosis · United States | 1 | Completed | Aug 2009 | 16 |
| NCT00852397Acute Coronary Syndrome · Japan | 2 | Terminated | Dec 2010 | 151 |
| NCT00787150Atrial Fibrillation · Japan | 2 | Completed | Sep 2009 | 222 |
How it is read
Names in the registry
- “Apixaban”, 38 entries
- “Apixaban 5 MG”, 2 entries
- “apixaban”, 2 entries
- “Apixaban 5 mg Oral Tablet”, 1 entry
- “Apixaban 5MG”, 1 entry
Conditions, from the studies’ own filings
- Venous Thrombosis, 7 studies
- Atrial Fibrillation, 6 studies
- Thrombosis, 4 studies
- Acute Coronary Syndrome, 4 studies
- Venous Thromboembolism, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.